Molecular-receptor-specific, non-toxic, near-infrared-emitting Au cluster-protein nanoconjugates for targeted cancer imaging
Source abstract
Abstract
Molecular-receptor-targeted imaging of folate receptor positive oral carcinoma cells using folic-acid-conjugated fluorescent Au(25) nanoclusters (Au NCs) is reported. Highly fluorescent Au(25) clusters were synthesized by controlled reduction of Au(+) ions, stabilized in bovine serum albumin (BSA), using a green-chemical reducing agent, ascorbic acid (vitamin-C). For targeted-imaging-based detection of cancer cells, the clusters were conjugated with folic acid (FA) through amide linkage with the BSA shell. The bioconjugated clusters show excellent stability over a wide range of pH from 4 to 14 and fluorescence efficiency of approximately 5.7% at pH 7.4 in phosphate buffer saline (PBS), indicating effective protection of nanoclusters by serum albumin during the bioconjugation reaction and cell-cluster interaction. The nanoclusters were characterized for their physico-chemical properties, toxicity and cancer targeting efficacy in vitro. X-ray photoelectron spectroscopy (XPS) suggests binding energies correlating to metal Au 4f(7/2) approximately 83.97 eV and Au 4f(5/2) approximately 87.768 eV. Transmission electron microscopy and atomic force microscopy revealed the formation of individual nanoclusters of size approximately 1 nm and protein cluster aggregates of size approximately 8 nm. Photoluminescence studies show bright fluorescence with peak maximum at approximately 674 nm with the spectral profile covering the near-infrared (NIR) region, making it possible to image clusters at the 700-800 nm emission window where the tissue absorption of light is minimum. The cell viability and reactive oxygen toxicity studies indicate the non-toxic nature of the Au clusters up to relatively higher concentrations of 500 microg ml(-1). Receptor-targeted cancer detection using Au clusters is demonstrated on FR(+ve) oral squamous cell carcinoma (KB) and breast adenocarcinoma cell MCF-7, where the FA-conjugated Au(25) clusters were found internalized in significantly higher concentrations compared to the negative control cell lines. This study demonstrates the potential of using non-toxic fluorescent Au nanoclusters for the targeted imaging of cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanocluster Synthesis and Applications · Advanced Nanomaterials in Catalysis · Carbon and Quantum Dots Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. 10.1016/S0958-1669(02)00282-310.1016/S0958-1669(02)00282-3 ↗
2. Haick H · J. Phys. D: Appl. Phys. · 2007 · 40 · 717310.1088/0022-3727/40/23/S01 ↗
3. 10.2217/17435889.2.5.68110.2217/17435889.2.5.681 ↗
4. 10.1126/science.271.5251.93310.1126/science.271.5251.933 ↗
5. 10.1038/9022810.1038/90228 ↗
6. 10.1007/s11671-007-9061-910.1007/s11671-007-9061-9 ↗
7. 10.1021/jp014259v10.1021/jp014259v ↗
8. 10.1021/ja048358910.1021/ja0483589 ↗
9. 10.1002/smll.20060061110.1002/smll.200600611 ↗
10. Shiraishi Y · Eur. Phys. · 2002 · 8 · 377
11. 10.1166/jnn.2007.92210.1166/jnn.2007.922 ↗
12. 10.1021/ja806804u10.1021/ja806804u ↗
13. 10.1021/bi00784a01010.1021/bi00784a010 ↗
14. 10.1021/nn800632j10.1021/nn800632j ↗
15. 10.1016/0167-4889(96)00041-910.1016/0167-4889(96)00041-9 ↗
16. 10.1016/j.taap.2009.02.02010.1016/j.taap.2009.02.020 ↗
17. 10.1126/science.131035910.1126/science.1310359 ↗
18. Antony A C · Blood · 1992 · 79 · 280710.1182/blood.V79.11.2807.2807 ↗
19. 10.1016/j.biomaterials.2009.09.09010.1016/j.biomaterials.2009.09.090 ↗
20. Manzoor K · Nanotechnology · 2009 · 20 · 06510210.1088/0957-4484/20/6/065102 ↗
21. 10.1021/bi00053a00110.1021/bi00053a001 ↗
22. Mohapatra S · Nanotechnology · 2007 · 18 · 38510210.1088/0957-4484/18/38/385102 ↗
23. Upstone S L · Encyclopedia of Analytical Chemistry · 2000 · 1699
24. 10.1021/bc050335b10.1021/bc050335b ↗
25. 10.1002/sia.74006030210.1002/sia.740060302 ↗
26. 10.1103/PhysRevB.33.540610.1103/PhysRevB.33.5406 ↗
27. 10.1021/ar960178j10.1021/ar960178j ↗
28. 10.1021/jp993867w10.1021/jp993867w ↗
29. 10.1021/jp004115110.1021/jp0041151 ↗
30. 10.1021/ja042218h10.1021/ja042218h ↗
31. 10.1021/jp800508d10.1021/jp800508d ↗
32. 10.1021/am900350r10.1021/am900350r ↗
33. 10.1002/chem.20090142510.1002/chem.200901425 ↗
34. 10.1016/j.toxlet.2008.10.01210.1016/j.toxlet.2008.10.012 ↗
35. 10.1016/j.toxlet.2008.06.86910.1016/j.toxlet.2008.06.869 ↗
36. 10.1016/j.febslet.2008.04.05710.1016/j.febslet.2008.04.057 ↗
37. Armstrong J · J. Androl. · 1998 · 19 · 41210.1002/j.1939-4640.1998.tb02034.x ↗
38. 10.1063/1.326296610.1063/1.3262966 ↗
39. Sonvico F · J. Drug Deliv. Sci. Technol. · 2005 · 15 · 40710.1016/S1773-2247(05)50080-7 ↗